Cargando…

Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer

Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Soukup, Alexandra A., Matson, Daniel R., Liu, Peng, Johnson, Kirby D., Bresnick, Emery H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664263/
https://www.ncbi.nlm.nih.gov/pubmed/34890222
http://dx.doi.org/10.1126/sciadv.abk3521
_version_ 1784613810692161536
author Soukup, Alexandra A.
Matson, Daniel R.
Liu, Peng
Johnson, Kirby D.
Bresnick, Emery H.
author_facet Soukup, Alexandra A.
Matson, Daniel R.
Liu, Peng
Johnson, Kirby D.
Bresnick, Emery H.
author_sort Soukup, Alexandra A.
collection PubMed
description Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe “conditionally pathogenic” (CP) enhancer motif variants that differentially affect hematopoietic development and regeneration. The Ets motif variant functioned autonomously in hematopoietic cells to disrupt hematopoiesis. Because an epigenetically silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics.
format Online
Article
Text
id pubmed-8664263
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-86642632021-12-16 Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer Soukup, Alexandra A. Matson, Daniel R. Liu, Peng Johnson, Kirby D. Bresnick, Emery H. Sci Adv Biomedicine and Life Sciences Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe “conditionally pathogenic” (CP) enhancer motif variants that differentially affect hematopoietic development and regeneration. The Ets motif variant functioned autonomously in hematopoietic cells to disrupt hematopoiesis. Because an epigenetically silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics. American Association for the Advancement of Science 2021-12-10 /pmc/articles/PMC8664263/ /pubmed/34890222 http://dx.doi.org/10.1126/sciadv.abk3521 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Soukup, Alexandra A.
Matson, Daniel R.
Liu, Peng
Johnson, Kirby D.
Bresnick, Emery H.
Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title_full Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title_fullStr Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title_full_unstemmed Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title_short Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
title_sort conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664263/
https://www.ncbi.nlm.nih.gov/pubmed/34890222
http://dx.doi.org/10.1126/sciadv.abk3521
work_keys_str_mv AT soukupalexandraa conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer
AT matsondanielr conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer
AT liupeng conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer
AT johnsonkirbyd conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer
AT bresnickemeryh conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer